Fintel reports that on November 4, 2024, Piper Sandler initiated coverage of Nektar Therapeutics (LSE:0UNL) with a Overweight recommendation.
https://www.nasdaq.com/articles/piper-sandler-initiates-coverage-nektar-therapeutics-lse-0unl-overweight-recommendation